Cue Biopharma, Inc. (NASDAQ: CUE) announced a 1‑for‑30 reverse stock split that will take effect at 5:00 p.m. Eastern Time on April 23, 2026. The split will consolidate approximately 97.7 million shares into about 3.3 million shares, raising the per‑share price and helping the company regain compliance with Nasdaq’s minimum bid‑price requirement of $1.00.
The reverse split will also adjust all outstanding stock options and warrants proportionally, increasing their exercise price while reducing the number of shares issuable. The adjustment will be reflected in trading on the CUE ticker beginning the next market day, April 24, 2026. The company’s board approved the split following shareholder approval at the 2026 Annual Meeting of Stockholders held on April 13, 2026, and the new CUSIP number for the post‑split shares is 22978P205. Prior to the split, the share price was approximately $0.67.
Cue Biopharma’s decision to implement the reverse split is part of a broader strategy to strengthen its balance sheet and maintain its Nasdaq listing amid ongoing liquidity challenges. The company has faced a significant cash burn rate and negative free cash flow, with a trailing‑12‑month revenue of $27.5 million as of December 31, 2025. The reverse split is a procedural step to increase the per‑share price, but it does not resolve the underlying financial pressures that require continued cost discipline and strategic focus on its autoimmune pipeline, particularly the CUE‑401 program.
Management has highlighted progress in advancing its Immuno‑STAT® platform. Former CEO Daniel Passeri noted that the company had “preserved the potential value of its clinical oncology programs by retaining requisite clinical capabilities to enable maturation of clinical survival data in the current ongoing Phase I trials of CUE‑101 and CUE‑102.” While the reverse split addresses Nasdaq compliance, the company’s long‑term prospects hinge on the successful development and commercialization of its pipeline and on securing additional capital to support ongoing research and development activities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.